Chad Deal, MD

216.444.5632

Chad Deal, MD

Appointed: 1999

Chad Deal, MD
Department: Rheumatologic and Immunologic Disease
Location: Cleveland Clinic Main Campus
Mail Code A50
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.5632
DeskDesk:216.444.6575
WorkFax:216.445.7569
Chad Deal, MD
Department: Rheumatologic and Immunologic Disease (Solon)
Location: Solon Family Health Center
Mail Code S0-40
29800 Bainbridge Road
Solon, OH 44139
WorkAppointment:440.519.6800
DeskDesk:216.444.6575
WorkFax:216.445.7569
Chad Deal, MD
Department: Orthopaedic Surgery
Location: Cleveland Clinic Main Campus
Mail Code A50
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.5632
WorkFax:216.445.7569
Chad Deal, MD
Department: Center for Geriatric Medicine
Location: Cleveland Clinic Main Campus
Mail Code A50
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.5632
WorkFax:216.445.7569
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

Chad Deal, MD, is Head of the Center for Osteoporosis and Metabolic Bone Disease and a board-certified Rheumatologist at Cleveland Clinic. He has specialty interests in osteoporosis and related conditions. Dr. Deal did his undergraduate work at Washington University, St. Louis, Mo. He attended medical school at the University of Arkansas, was inducted into Alpha Omega Alpha, and graduated in 1977. His internship and residency were at Boston City Hospital in Boston, Mass. He completed a fellowship in arthritis and connective tissue diseases at Boston University School of Medicine in 1982.

Dr. Deal has been in Cleveland since 1984. He was Associate Professor of Medicine at the Case Western Reserve University School of Medicine until 1999, when he left to become Head of the Center for Osteoporosis and Metabolic Bone Disease at Cleveland Clinic.

Dr. Deal has been an active investigator in multiple clinical trials relating to arthritis and osteoporosis. He has been an investigator in numerous multicenter trials, including drug trials using teriparatide (PTH) with raloxifene, zoledronic acid after teriparatide, and novel anabolic agents. He is author of over 50 publications.

He is a past member on the Committees on Rheumatologic Care, Training and Workforce, and Finance for the American College of Rheumatology. He is currently on the Board of Directors of the American College of Rheumatology. He is a member of the Interspecialty Medical Council of the NOF for the ACR. Dr. Deal is a reviewer for numerous rheumatology, orthopedic and osteoporosis journals. He has received the National Volunteer Service Citation from the Arthritis Foundation, and has been awarded Teacher of the Year in Rheumatic Diseases at Cleveland Clinic. He has been named one of the best doctors in Cleveland.

Learn from Dr. Deal on how osteoporosis, the ‘silent thief of bone,’ can be prevented, detected and treated. Both men and women get osteoporosis and it's a common misconception that only women have osteoporosis.

Professional Highlights

  • Board of Directors, American College of Rheumatology

Education & Fellowships

Fellowship - Boston Medical Center
Rheumatology
Boston, MA USA
1982
Residency - Boston Medical Center
Internal Medicine
Boston, MA USA
1980
Internship - Boston Medical Center
Internal Medicine
Boston, MA USA
1978
Medical School - University of Arkansas College of Medicine
Little Rock, AR USA
1977
Undergraduate - Washington University
History & Biology
St. Louis, MO USA
1973

Certifications

  • Internal Medicine
  • Internal Medicine- Rheumatology

Specialty Interests

Osteoporosis, metabolic bone disease, steroid osteoporosis, connective tissue disease, Paget’s Disease

Awards & Honors

Best Doctor, Cleveland magazine

Memberships

  • American College of Rheumatology
  • American Society of Bone and Mineral Research
  • International Society of Clinical Densitometry

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 6/27/2014, Dr. Deal has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Deal received fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Amgen, Inc.
  • Lilly USA, LLC
  • Theralogix, LLC

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
Cleveland Clinic Mobile Site